ZA200105617B - Bifidobacterium in the treatment of inflammatory disease. - Google Patents
Bifidobacterium in the treatment of inflammatory disease. Download PDFInfo
- Publication number
- ZA200105617B ZA200105617B ZA200105617A ZA200105617A ZA200105617B ZA 200105617 B ZA200105617 B ZA 200105617B ZA 200105617 A ZA200105617 A ZA 200105617A ZA 200105617 A ZA200105617 A ZA 200105617A ZA 200105617 B ZA200105617 B ZA 200105617B
- Authority
- ZA
- South Africa
- Prior art keywords
- strain
- bifidobacterium
- formulation
- cells
- lactobacillus salivarius
- Prior art date
Links
- 241000186000 Bifidobacterium Species 0.000 title claims description 77
- 238000011282 treatment Methods 0.000 title claims description 28
- 208000027866 inflammatory disease Diseases 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims description 55
- 238000009472 formulation Methods 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 48
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 41
- 241000699670 Mus sp. Species 0.000 claims description 41
- 241000894006 Bacteria Species 0.000 claims description 38
- 239000006041 probiotic Substances 0.000 claims description 32
- 235000018291 probiotics Nutrition 0.000 claims description 32
- 230000000529 probiotic effect Effects 0.000 claims description 30
- 230000012010 growth Effects 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 27
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 27
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 19
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 18
- 210000000987 immune system Anatomy 0.000 claims description 17
- 210000000941 bile Anatomy 0.000 claims description 15
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 238000011321 prophylaxis Methods 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000004051 gastric juice Anatomy 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 230000002496 gastric effect Effects 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 241001427851 Lactobacillus salivarius UCC118 Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 210000002919 epithelial cell Anatomy 0.000 claims description 8
- 230000002519 immonomodulatory effect Effects 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 235000013406 prebiotics Nutrition 0.000 claims description 8
- 230000009885 systemic effect Effects 0.000 claims description 8
- 235000013618 yogurt Nutrition 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 230000000845 anti-microbial effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 241000589516 Pseudomonas Species 0.000 claims description 5
- 241000191940 Staphylococcus Species 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 208000010399 Wasting Syndrome Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 108010067770 Endopeptidase K Proteins 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 208000002389 Pouchitis Diseases 0.000 claims description 2
- 108010059712 Pronase Proteins 0.000 claims description 2
- 235000020167 acidified milk Nutrition 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- 239000002366 mineral element Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- 108700012920 TNF Proteins 0.000 claims 1
- 229920001817 Agar Polymers 0.000 description 18
- 239000008272 agar Substances 0.000 description 18
- 206010012735 Diarrhoea Diseases 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 238000011579 SCID mouse model Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 230000028709 inflammatory response Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000770 proinflammatory effect Effects 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 239000003613 bile acid Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 229940096397 interleukin-8 Drugs 0.000 description 7
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000131482 Bifidobacterium sp. Species 0.000 description 6
- 239000004380 Cholic acid Substances 0.000 description 6
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 6
- 108010007979 Glycocholic Acid Proteins 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 6
- 229960002471 cholic acid Drugs 0.000 description 6
- 235000019416 cholic acid Nutrition 0.000 description 6
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 6
- 229940099347 glycocholic acid Drugs 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 208000016261 weight loss Diseases 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 5
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 5
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940076144 interleukin-10 Drugs 0.000 description 5
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 244000005706 microflora Species 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010093031 Galactosidases Proteins 0.000 description 4
- 102000002464 Galactosidases Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 3
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010035039 Piloerection Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001142 anti-diarrhea Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 3
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 229960000598 infliximab Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000005371 pilomotor reflex Effects 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000252983 Caecum Species 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012630 HPLC buffer Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102100040865 Phospholipase A2 group XV Human genes 0.000 description 2
- 101710127148 Phospholipase A2 group XV Proteins 0.000 description 2
- 241001417524 Pomacanthidae Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000011861 anti-inflammatory therapy Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 102000052301 human GNAZ Human genes 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 231100000586 procarcinogen Toxicity 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
- 208000007416 Aberrant Crypt Foci Diseases 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000031670 Saccharopolyspora thermophila Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010054000 Type II hypersensitivity Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010961 commercial manufacture process Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000024833 regulation of cytokine production Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000935 short-term exposure limit Toxicity 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 230000008026 type II hypersensitivity Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Description
- bo . . BIFIDOBACTERIUMTN THE TREATMENT OF INFLAMMATORY DISEASE —
Introduction
This invention relates to probiotic Bifidobacterium strains which have various h] applications in foodstuffs and in medicine. More particularly, the invention relates to probiotic strains of bifidobacteria which are capable of beneficially modifying and consequently alleviating observable symptoms in inflammatory disease.
Consumers are becoming increasingly aware of matters which may be necessary for maintenance of their environment, health and nutrition. In response, scientific research has focussed upon the roles that diet, stress, and modern medical practices (e.g. antibiotics and radiotherapy) may play in threatening human health. In particular, population dynamics shifting towards older societies are increasing the incidence of illnesses which may be caused by deficient or compromised microflora such as gastrointestinal tract (GIT) infections, constipation, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) —
Crohn's disease and ulcerative colitis, food allergies, antibiotic-induced diarrhoea, cardiovascular disease, and certain cancers (e.g. colorectal cancer).
Probiotics have been defined as live microbial food supplements which beneficially affect the host by improving the intestinal microbial balance, or more broadly, as living micro-organisms, which upon ingestion in certain numbers, exert health effects beyond inherent basic nutrition. Cocktails of various micro- organisms, particularly species of Lactobaciilus and Saepiococcus, have traditionally been used in fermented dairy products to promote health.
In recent years the commercial manufacture and marketing of functional foods (foods which affect functions of the body in a targeted manner so as to bring about positive affects on physiology and nutrition), particularly probiotic (Acidophilus-
Bifidus) yoghurts, has spread from the well-established Japanese niche market
‘ . . place into the lucrative and expanding European Union. While a number of probiotic bacteria of human origin are now being exploited commercially (e.g., L. acidophilus LA-1), many consumers, consumer organisations, and members of the scientific community are sceptical of such products and their publicised probiotic claims. The diary-food industry is therefore under considerable pressure to scientifically validate these new probiotic food products.
Criteria which have been suggested for the selection of potentially effective probiotic micro-organisms may be summarised as follows: human origin, non- pathogenic behaviour, resistance to technological processes (i.e., viability and activity in delivery vehicles), resistance to gastric acidity and bile toxicity, adhesion to gut epithelial tissue, ability to colonise the GIT, production of antimicrobial substances, ability to modulate immune responses, and the ability to influence metabolic activities (e.g., cholesterol assimilation, lactase activity, vitamin production) (Huis in't Veld J, Shortt C. Selection criteria for probiotic micro-organisms. In; Leeds, A.R., Rowland, LR. eds. Gut Fora and Health —
Past, Present and Future. London: The Royal Society of Medicine Press Lid, 1996:19-26).
Bifidobacteria are one of several predominant culturable bacteria present in the colonic microflora.
The functions of endogenous bifidobacteria in the colon have not been completely elucidated. However, it is recognised that exclusively breast-fed infants have a reduced risk of diarrhoea compared with formula-fed infants. The fact that these infants have greater numbers of colonic bifidobacteria may in part explain this observed health advantage as the occupation of available niches in the GIT by : large numbers of nonpathogenic bifidobacteria may help prevent bacterial infection. The pathogenesis of Crohn's disease is thought to be related to colonic bacterial microflora (Targan, S. and Shanahan, F. Inflammatory bowel disease:
From bench to bedside. Williams and Wilkins 1994.) It has recently been found
SR | _WO.0M42168 Cl _. PCTIE00/00008 . that patients suffering from active Crohn’s disease have significantly less - recoverable bifidobacteria in their faeces compared with healthy individuals. This reduction in bifidobacteria numbers was observed to be directly correlated with decreased levels of B-D galactosidase production and activity (Favier, C. et af,
Dig. Dis. Sci. 1997;42:817-822). B-D galactosidase is an enzyme produced by bifidobacteria. These results support suggestions proposed in other studies that strains of bifidobacteria may play important roles in maintaining a balanced healthy intestinal microflora.
Bifidobacteria are considered to be probiotics as they are living organisms which exert healthy effects beyond basic nutrition when ingested in sufficient numbers.
Numerous ingested bifidobacteria must reach the site of action in the gut in order to exert a probiotic effect. A minimum level of approximately 105-107 viable bifidobacteria per gram intestinal contents has been suggested (Bouhnik, Y., Lait 1993: 73:241-247). There are reports in the literature which show that in vivo : studies completed in adults and in infants indicate that some strains of bifidobacteria are capable of surviving passage through the gastrointestinal tract. } Significant differences have been observed between the abilities of different bifidobacteria strains to tolerate acid and bile salts, indicating that survival is an important criterion for the selection of potential probiotic strains.
Ingestion of bifidobacteria can improve gastrointestinal transit.
Furthermore, indirect evidence in humans demonstrates that consuming milk fermented by bifidobacteria can lead to reduced levels of certain faecal enzymes such as B-D galactosidase implicated in the conversion of procarcinogens to carcinogens (Bouhnik Y. et af, Eur. J. Clin. Nutr. 1996;50:269-273). Faecal-borne putrefaction metabolities such as p-cresol, indole and ammonia were also reduced when subjects consumed milk fermented by Bifidobacterium longum and S. thermophilus (Takiguchi, R. er al. Bifidus — Flores, Fructus et Semina 1996,9:135-
Antimicrobial activity has been reported to be associated with bifidobacteria.
Also, bifidobacteria have been shown to modulate various parameters of the immune system.
Mucosal inflammation in IL-10 deficient mice has been reported to be reduced by feeding the subject animals a preparation of lactic acid bacteria (Madsen, K. er 2/.
Gastroenterol. 1997;112:A1030.). Further studies completed in rats have demonstrated that ingestion of bifidobacteria can suppress aberrant crypt foci (early preneoplastic lesions) formation in the colon (Kulkarni, N. and Reddy, B.
Proc. Soc. Experim. Biol. Med. 1994; 207,278-283.) in addition to significant decreases in colon tumor incidence and in the numbers of tumors present (Singh,
I. er al Carcinogenesis 1997;18:833-841).
There is an on-going search for probiotic strains with particular beneficial effects on nutrition and therapy and on health generally.
Statements of Invention
The invention provides a strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract which is significantly immunomodulatory tcliowing oral consumption in humans.
The strain of Bifidobacterium preferably effects changes in an immunological marker when introduced into a system comprising cells which interact with the immune system and cells of the immune system. Preferably the cells which interact with the immune system are epithelial cells. Preferably the immunological marker is a cytokine, especially TNFa.
In a preferred embodiment the cells which interact with the immune system and the immune system cells are of matched origin.
: LL. WOO00/M42168 PCT/IE00/00008 . The cells which interact with the immune system are of gastrointestinal, . respiratory or genitourinary origin.
The cells of the immune system are preferably of gastrointestinal, respiratory or genitourinary origin.
The invention also provides a strain of Bifidobacterium longum infantis isolated from resected and washed human gastrointestinal tract which is significantly immunomodulatory following oral consumption in humans.
The strain of Bifidobacterium which has significant anti-inflammatory effect following oral consumption in humans.
The strain of Bifidobacterium is preferably isolated from resected and washed human gastrointestinal tract which is capable of combating the effects of inflammatory bowel disease, said capability being maintained in the presence of physiological concentrations of human bile and human gastric juice. The capability of combating the effects of inflammatory bowel disease is measured by measuring a reversal of a wasting disease induced in severe combined immunodeficient recipient mice (SCID) which have been administered purified
CD4*, CD4SRB"® T cells.
The capability of the strain of Bifidobacterium longum infantis to combat the effects of inflammatory bowel disease can also be measured by measuring the reduction in colonic inflammation in IL-10 deficient mice (IL-107 129 Svex stain) following administration of one or more of the strains of Bifidobacterium longum infantis according to the invention alone or in combination with a strain of
Lactobacillus salivarius as hereinafter defined.
Interleukin 10 (IL-10) is an important regulatory cytokine that supresses effector functions of macrophage/monocytes, T helper 1 (Thl) cells, and natural killer
- cells. In addition, IL-10 augments proliferation and differentiation of B cells.
Murine models lacking the I-10 gene spontaneously develop inflammatory bowel disease and gastrointestinal tumors. The gastrointestinal flora have been implicated in the pathogenesis of these disease states as germ free animals do not develop disease.
The strain of Bifidobacterium preferably has inhibitory activity against a broad range of Gram positive and Gram negative bacteria.
Preferably the strain of Bifidobacterium exhibits a broad-spectrum of activity against bacteria including Staphylococcus, Pseudomonas, Coliform and Bacillus species.
In a particular aspect the invention provides strain of Bifidobacterium longum infantis UCC35624 or mutant or variant thereof.
A deposit of Bifidobacterium Jongum infantis strain UCC 35624 was made at the
National Collections of Industrial and Marine Bacteria Limited (NCIMB) on
January 13, 1999 and accorded the accession number NCIMB 41003
Ir: one embodiment the mutant is a genetically modified mutant,
In one embodiment the variant is a naturally occurring variant of Bifidobacterium longum mfantis UCC35624.
The strain of Bifidobactersfum may be in the form of viable cells. Alternatively the strain of Bifidobacterium is in the form of non-viable cells.
The invention also provides an antimicrobial agent obtained from a strain of
Bifidobacterium of the invention which is antagonistic to the growth of other
Organisms.
. "In a further aspect the invention provides a formulation which comprises a strain = of Bifidobacterium of the invention.
The formulation may comprise two or more strains of Bifidobacterium.
The formulation may include another probiotic material. Alternatively or additionally the formulation includes a prebiotic material.
The formulation may which include a strain of Lactobacillus salivarius.
The strain of Lactobacillus salivarius may be in the form of viable cells or in the form of non-viable cells.
The Lactobacillus salivarius is preferably isolated from resected and washed human gastrointestinal tract, the Lactobacillus salivarius being significantly immunomodulatory following oral consumption in humans. Preferably the strain of Lactobacillus salivarius is isolated from resected and washed human gastrointestinal tract which inhibits a broad range of Gram positive and Gram negative micro-organisms.
In a preferred embodiment the strain of Lactobacillus salivarius secretes a product having antimicrobial activity into a cell — free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase
E, the inhibitory properties of said strain and its secretory products being maintained in the presence of physiological concentration of human bile and human gastric juice.
Such strains of Lactobacillus salivarius are disclosed in WO 98/35014. )
- Ideally the strain of Lactobacillus salivariusis Lactobacillus salivarius strain UCC 118 or a mutant or variant thereof. The mutant is a genetically modified mutant.
The variant may be a naturally occurring variant of Lactobacillus salivarius.
A deposit of Lactobacillus salivarius strain UCC 118 was made at the NCIMB on
November 27, 1996 and accorded the accession number NCIMB 40829.
Preferably the formulation includes an ingestable carrier. The ingestable carrier may be a pharmaceutically acceptable carrier such as a capsule, tablet or powder.
The ingestable carrier may be a food product such as acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings or beverages.
The formulation may comprise a protein and/or peptide, in particular proteins and/or peptides that are rich in glutamine/glutamate, a lipid, a carbohydrate, a vitamin, mineral and/or trace element.
In one embodiment the Bifidobacterium is present at more than 10° cfit per gram of delivery system.
In another embodiment the formulation includes an adjuvant.
The formulation may include a bacterial component. The formulation may alternatively or additionally include a drug entity. The formulation may also include a biological compound.
The formulation may be in a form for oral immunisation.
The invention further provides a strain of Bifidobacterium or a formulation thereof for use in foodstuffs.
: ._WOO0MM42168 | oo PCT/IE00/00008 - In another aspect the invention provides a strain of Bifidobacterium or a — formulation thereof for use as a medicament.
The strain or formulation may be for use in the prophylaxis and/or treatment of undesirable inflammatory activity.
The strain or formulation may be for use in the prophylaxis and/or treatment of undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohns disease or ulcerative colitis, irritable bowel syndrome, pouchitis or post infection colitis.
The undesirable inflammatory activity may be due to cancer.
In addition the strain or formulation may be for use in the prophylaxis and/or treatment of gastrointestinal cancer(s).
The strain or formulation may be used for the prophylaxis of cancer. Further, the strain or formulation may be for use in the prophylaxis and/or treatment of systemic disease such as rheumatoid arthritis.
The strain or formulation may be for use in the prophylaxis and/or treatment of autoimmune disorders due to undesirable inflammatory activity.
The strain or formulation may be for use in the prophylaxis and/or treatment of cancer due to undesirable inflammatory activity.
The strain or formulation may be for use in the prophylaxis and/or treatment of diarrhoeal disease due undesirable inflammatory activity, such as Clostridium } difficile associated diarrhoea, Rotavirus associated diarrhoea or post infective diarrhoea.
In the accompanying drawings:
Fig. 1 is a graph of cfu/ml! versus time for Bifidobacterium longum infantis strain 35612 as described in Example 2;
Fig. 2 is a graph of cfu/mi versus time for Bifidobacterium longum infantis strain 35624 as described in Example 2;
Fig. 3 is a graph of percentage weight change versus time (days) for five
SCID mice (1-5) administered strain UCC 35624 as described in Example 5;
Fig. 4 is a graph of average percentage weight change versus ime (days) for the SCID mice (1-5) administered strain UCC 35624 as described in :
Example 3,
Fig. 5 is a graph of percentage weight change versus time (days) for mice (6-10) administered a combination of strains Lactobacillus salivarzus UCC 118 and UCC 35624 as described in Example 5;
Fig. 6 is a graph of average percentage weight change versus ime (days) for mice (6-10) administered a combination of strains UCC 118 and UCC 35624 as described in Example 3,
Fig. 7 is a graph of percentage weight change versus time (days) for mice (11-15) administered a combination of strains UCC 118 and UCC 35624 as described in Example 5;
: . ___WOO00/42168 oo Ce ~__PCT/IE00/00008 A . Fig. 8 is a graph of average percentage weight change versus time (days) . for mice (11-15) administered a combination of strains UCC 118 and UCC 35624 as described in Example 5;
Fig. 9 is a bar chart of TNFa levels in patient and control samples in the presence of PBMCs and Bifidobacteria longum infantis as described in
Example 7,
Fig. 10 is a bar chart showing TNFa and IL-8 levels in co-cultures of epithelial cells, PBMCs and Bifidobacterium longum infantis as described in Example 7. Controls represent co-cultures of epithelial cells and
PBMCs alone;
Fig. 11 are bar charts of peripheral blood cytokine levels following consumption of Bifidobacterium longum infantis by healthy human . volunteers (n=18) for three weeks as described in Example 8; ] Fig. 12 are bar charts of serum levels of TNFa and IL-1RA following consumption of Bifidobacterium longum infantis to healthy human volunteers (n=18) as described in Example 8;
Fig.13 is a bar chart of TNFa levels in cell-free spent culture supernatant of
Bifidobacterium longum infantis and an MRS control as described in
Example 9;
Fig.14 is a diagrammatic representation of a SCID mouse lower intestine after treatment with Bifidobacterium longum infantis; and
Fig.15 is a diagrammatic representation of the lower intestine of an untreated SCID mouse .
We have isolated strains of probiotic bacteria which are capable of beneficially modifying and consequently alleviating observable symptoms in inflammatory disorders. These strains and the formulations prepared may be used in a variety of foodstuffs and medicaments to combat the effect of inflammatory disorders.
In vivo and in vitro studies were carried out using the probiotic bacteria strains. It was found that humans fed with yoghurt containing Bifidobacterium longum infantis UCC35624 show marked decreases in their systemic levels of IL-8. This strain may therefore have potential application in the treatment of a range of inflammatory disorders, particularly if used in combination with current anti- inflammatory therapies, such as non-steroid anti-inflammatory drugs (NSATDs) or
Infliximab.
The consumption of Bifidobacterium longum infantis by SCID mice was also examined. While this experiment significantly attenuated inflammatory activity, ; mice consuming Bifidobacterium longum infantis retained solid stools while control mice suffered from diarrhoea. This anti-diarrhoeal effect could be related tc the ant-inflammatory activity of this invention, possibly mediated via cAMP modulation.
It is unknown whether intact bacteria are required to exert an anti-inflammatory effect or if individual active components of the invention can be utilised alone.
Proinflammatory components of certain bacterial strains have been identified.
The proinflammatory effects of gram-negative bacteria are mediated by lipopolysaccharide (LPS). LPS alone induces a proinflammatory network, partially due to LPS binding to the CD14 receptor on monocytes. It is assumed that components of probiotic bacteria possess anti-inflammatory activity, due to the effects of the whole cell. Upon isolation of these components, pharmaceutical grade manipulation is anticipated.
. i | - __WOO00/42168 SE ~. . _ PCT/IE00/00008 a : The general use of Bifidobacterium longum infantis UCC35624 is in the form of ; viable cells. However, it can also be extended to non-viable cells such as killed cultures or compositions containing beneficial factors expressed by
Bifidobacterium longum infantis UCC35624. This could include thermally killed micro-organisms or micro-organisms killed by exposure to altered pH or subjection to pressure. With non-viable cells product preparation is simpler, cells may be incorporated easily into pharmaceuticals and storage requirements are much less limited than viable cells. Lactobacillus casei YIT 9018 offers an example of the effective use of heat killed cells as a method for the treatment and/or prevention of tumour growth as described in US Patent No. US4347240.
The invention will be more clearly understood from the following Examples.
Example 1
Isolation of probiotic bacteria
Appendices and sections of the large and small intestine of the human G.LT., obtained during reconstructive surgery, were screened for probiotic bacterial strains as shown in Table 1.
, : . Table 1
Gastrointestinal tract tissue samples screened for the presence of probiotic bacteria
Sample Location
A Heum
B Colon
Cc Tleal-caecal region
D Appendix
E Appendix
F lleum
G Ileal-caecal region p a
All samples were stored immediately after surgery at -80°C in sterile containers.
Frozen tissues were thawed, weighed and placed in cysteinated (0.05%) one quarter strength Ringers’ solution. Each sample was gently shaken to remove loosely adhering microorganisms (termed — wash “W’). Following transfer to a second volume of Ringers’ solution, the sample was vortexed for 7 min to remove tightly adhering bacteria (termed — Sample ‘S’). In order to isolate tissue embedded bacteria, samples A, B and C were also homogenised in a Braun blender (termed — homogenate ‘H’). The solutions were serially diluted (dilution 10" from a wash sample was labelled W1, dilution 10? was labelled W2 and the same labelling system was used for the ‘S’ and ‘H’ samples) and spread-plated (100ul) on to the following agar media; RCM (reinforced clostridial media) and
RCM adjusted to pH 5.5 using acetic acid; TPY (trypticase, peptone and yeast extract), Chevalier, P. et al (1990) J Appl Bacteriol 68, 619-624). MRS
- ~ (deMann, Rogosa and Sharpe); ROG (acetate medium (SL) of Rogosa); LLA oo (Liver-lactose agar of Lapiere); BHI (brain heart infusion agar); LBS(
Lactobacillus selective agar) and TSAYE (tryptone soya agar supplemented with 0.6% yeast extract). All agar media was supplied by Oxoid Chemicals with the exception of TPY agar. Plates were incubated in anaerobic jars (BBL, Oxoid) using CO, generating kits (Anaerocult A, Merck) for 2-5 days at 37°C.
Gram positive, catalase negative rod-shaped or bifurcated/pleomorphic bacteria isolates were streaked for purity on to complex non-selective media (TPY).
Isolates were routinely cultivated in TPY medium unless otherwise stated at 37°C under anaerobic conditions. Presumptive Bifidobacteria species were stocked in 40% glycerol and stored at -20° and -80°C.
Fermentation end-product analysis a Metabolism of the carbohydrate glucose and the subsequent organic acid end- products were examined using an LKB Bromma, Aminex HPX-87H High
Performance Liquid Chromatography (HPLC) column. The column was maintained at 60°C with a flow rate of 0.6 ml/min (constant pressure). The
HPLC buffer used was 0.01 N H,SO,. Prior to analysis, the column was calibrated using 10 mM citrate, 10 mM glucose, 20 mM lactate and 10 mM acetate as standards. Cultures were propagated in modified MRS broth for 1-2 days at 37°C anaerobically. Following centrifugation for 10 min at 14,000 g, the supernatant was diluted 1:5 with HPLC buffer and 200 pl was analysed in the
HPLC. All supernatants were analysed in duplicate.
Biochemical and physiological characterisation
Biochemical and physiological traits of the bacterial isolates were determined to aid identification. Nitrate reduction, indole formation and expression of B- galactosidase activity were assayed. Growth at both 15°C and 45°C and protease
. activity on gelatin were determined. Growth characteristics of the strains in litmus milk were also assessed.
Antibiotic sensitivity profiles
Antibiotic sensitivity profiles of the isolates were determined using the ‘disc susceptibility’ assay. Cultures were grown up in the appropriate broth medium for 24-48 h, spread-plated (100ul) onto agar media and discs containing known concentrations of the antibiotics were placed onto the agar. Strains were examined for antibiotic sensitivity after 1-2 days incubation at 37°C under anaerobic conditions. Strains were considered sensitive if zones of inhibition of
Imm or greater were seen.
Isolation of Bifidobacteria sp.
Seven tissue sections taken from the human G.1.T. were screened for the presence of strains belonging to the Bifidobacterium genus. There was some vanation between tissue samples as follows. Samples A (ileum) and E (appendix) had the lowest counts with approximately 10° cells isolated per gram of tissue. In comparison, greater than 10° cfu/g tissue were recovered from the other samples.
Similar numbers of bacteria were isolated during the ‘wash’ and ‘sampie’ steps with slightly higher counts in the ‘sample’ solutions of F (ileum) and G (ileal- caecal). Of those screened for tightly-adhering bacteria (homogenised), C (ileal- caecal) was the only tissue section that gave significant counts.
During the screening of some tissue sections, for example C and B, there was not a direct correlation between counts obtained during a dilution series. This would indicate that some growth factors, either blood or tissue derived were being provided for the growth of the fastidious bacteria in the initial suspension which was subsequently diluted out.
- Strain selection and characterisation a
Approximately fifteen hundred catalase negative bacterial isolates from different samples were chosen and characterised in terms of their Gram reaction, cell size and morphology, growth at 15°C and 45°C and fermentation end-products from glucose. Greater than sixty percent of the isolates tested were Gram positive, homofermentative cocci arranged either in tetrads, chains or bunches. Eighteen percent of the isolates were Gram negative rods and heterofermentative coccobacilli.
The remaining isolates (twenty-two percent) were predominantly homofermentative coccobacilli. Thirty eight strains were characterised in more detail- 13 isolates from G; 4 from F; 8 from D; 9 from C; 3 from B and 1 from E.
All thirty eight isolates tested negative both for nitrate reduction and production of indole from tryptophan.
Antibiotic sensitivity profiles
Antibiotics of human clinical importance were used to ascertain the sensitivity profiles of selected bifidobacteria. The bifidobacteria tested were sensitive to ampicillin, amoxycillin ceftaxime, ceftriaxone, ciprofloxacin, cephradine, rifampicin, amikacin, gentamicin and chloramphenicol. They were also resistant to netilmicin, trimethoprim, nalidixic acid, cefuroxime, vancomycin and tetracycline.
. Example 2
Acid Resistance
The first line of host defence that a micro-organism reaches following human consumption is gastric acid in the stomach. A key factor influencing bacteria is survival in gastric juice. The survival and growth of Bifidobacterium longum infantis strains 35612 and 35624 in a low pH environment were examined. The strains were routinely cultured in trypticase-peptone-yeast extract (TPY) medium at 37°C under strict anaerobic conditions (BBL Gas jars using the Merck
Anaerocult A gas pak system) for 12-24h. Human gastric juice was obtained from healthy subjects by aspiration through a nasogastric tube (Mercy Hospital, Cork,
Ireland). It was immediately centrigued at 13,000 g for 30 min. to remove ail solid particles, sterilised through 0.45um filters and 0.2um filters and stored at 4°C. The pH and pepsin activity were measured prior to experimental use.
Pepsin activity was measured using the quantitative haemoglobin assay (Guantam, S. and R.S. de la Motte. 1989. Proteolytic enzymes, a practical approach. Chapter 3. R.J. Beynon and J.S. Bond(eds.), IRL Press, Oxford
University Press; Dawson, RM. 1969, pH and buffers. In Data for Biochemical
Research p 138. R.M. Dawson, D.C. Elliot and K.M. Jones(eds.), Clarendon
Press, Oxford). Survival of the strains at low pH in wvzro was mvestigated using the following assays: (a) Cells were harvested from fresh overnight cultures, washed twice in phosphate buffer (pH 6.5) and resuspended in MRS broth adjusted to pH 3.5, 3.0, 2.5 and 2.0 (with IN HCI) to a final concentration of approximately 10° cfu/ml.
Cells were incubated at 37°C and survival measured at intervals of 5, 30, 60 and 120 min. using the plate count method.
The strains survived with no loss of viability at pH 3.5. At pH 2.5 there was a 3 log reduction over the 60 min. incubation period as depicted in Figs. 1 and 2.
WO .00/42168 a eo... PCT/IE00/00008 ee
Survival of strains of Bifidobacterjum in human gastric juice
Fresh overnight cultures were harvested, washed twice in buffer (pH 6.5) and resuspended in human gastric juice to a final concentration of 10° cfu/ml.
Survival was monitored over a 30-60 min incubation period at 37°C. The experiment was performed using gastric juice at pH 1.2 (unadjusted) and pH 2.0 and 2.5 (adjusted using IN NaOH).
Survival of the strains was increased in gastric juice at pH 2.0, when compared with gastric juice at pH 1.2. After 30 min incubation no viable cells were recovered at either pH as shown in Table 2.
- Table 2
Survival of Bifidobacterium sp. in human gastric juice*
TIME (min)
STRAIN pH 0 5 30 60 35612 1.2 7.56 0.00 0.00 0.00 2.0 6.27 6.31 2.88 0.00 35624 1.2 5.96 4.18 0.00 0.00 2.0 6.33 6.32 0.00 0.00 35652 1.2 6.16 3.78 0.00 0.00 2.0 8.45 8.40 3.45 0.00 35648 1.2 6.00 0.00 0.00 0.00 2.0 7.8% 6.45 3.00 (1.00 35687 1.2 6.68 0.00 0.00 (4.00 2.0 8.75 8.77 3.34 0.00
BO 2.0 8.41 8.56 8.42 8.43 ) 2.0 8.39 8.56 4.64 0.00 6.3 2.0 8.7% 8.75 8.25 3.42
B 6 2.0 8.15 8.02 0.00 0.00 longum *survival expressed as 16g o cfu/ml [=
} Example 3 =
Bile resistance
In the evaluation of the effectiveness of using lactic acid bacteria as beneficial members of the gastrointestinal tract, it is considered that resistance to bile acids is an important biological strain characteristic required for survival in this hostile environment and in addition they must not impinge on the health of the host by producing toxic compounds such as deoxycholic (DCA) and lithocholic acid (LCA) which have been implicated in a number of cytotoxic phenomena.
A number of Bifidobacterium longum infantis strains were streaked onto TPY agar plates supplemented with porcine bile (B-8631, Sigma Chemical Co. Itd.,
Poole) at concentrations of 0.3, 0.5, 1.0, 1.5, 5.0 and 7.5% (w/v) (Legrand-
Defretin, R. er al, Lipids 1991; 26 (8), 578-583). Porcine bile is the closest in
BN composition to human bile with respect to bile salt/cholesterol and phospholipid/cholesterol ratios. Plates were incubated at 37°C under anaerobic conditions and growth was recorded after 24-48 h. Strain 35624 was found to be strongly bile resistant and grew to confluence at up to 55 porcine bile as shown in
Table 3.
} Table 3
Growth of Bifidobacterium sp. isolates in the presence of porcine bile % (w/v) PORCINE BILE
STRAIN
0.0 0.3 0:5 1.0 1.5 5.0 7.5 34612 + - - - - - - 35624 + + + + + + - 35652 + - - - - - - 35658 + + + + - . i; 35687 + - - - - - - 3 -, no growth; +, confluent growth SS
Human bile was obtained from several human gall bladders and sterilised at 80°C for 10 min. The bile acid composition of human bile was determined using reverse phase High Performance Liquid Chromatography (HPLC) in combination
HY with a pulsed amperometric detector according to the method of Dekker, R.R. et al., Chromatographia, 1991, 31 (11/12), 255-256. Human bile was added at a concentration of 0.3% (v/v). Freshly streaked cultures were examined for growth after 24 and 48 h.
Strain 35624 was capable of growth in the presence of physiologically relevant human bile (0.3% (v/v)).
Growth of the strains was examined in the presence of individual conjugated and deconjugated bile acids. Under physiological conditions bile acids are often found as sodium salts. The strains were screened for growth on TPY agar containing the conjugated and deconjugated sodium salts of each of the following bile acids.
(a) conjugated form: glycocholic acid (GCA); glycodeoxycholic acid (GDCA), and glycochenodeoxycholic acid (GCDCA), (b) deconjugated form: lithocholic acid (LCA); chenodeoxycholic acid (CDCA); deoxycholic acid (DCA) and cholic acid (CA). For each bile acid concentrations of 1, 3 and 4 mM were used. Growth was recorded after 24 and 48 h anaerobic incubation.
The five strains studied grew on agar medium supplemented with 5 mM GCA and GCDCA and on agar medium supplemented with 1 mM GDCA as shown in
Table 4. Strain 35624 was resistant to concentrations of 5 mM LCA (data not shown) and strains 35612 and 35624 were capable of growth at concentrations of 5 mM CA as shown in Table 5. No growth was observed in the presence of 1 mM
CDCA (data not shown).
. Table 4
Growth of Bifidobacterium sp. isolates in the presence of glycine-conjugated bile acids
BILE ACIDS (mM)
STRAIN GCDCA GDCA | GCA lo 1 3 50 1 3 5,0 1 3 5 35612 + + + + | + + + ++ + + + 35624 + 4+ + ++ + + +++ +4 35652 ESSERE 35658 EEE TEE EE 35687 | + + + + + + 4 +++ FF -, no growth; +, confluent growth
GCDCA, glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid; CGA, glycocholic acid.
. - : - ~WO00/42168 FE eo... PCT/IE00/00008 ee : | Table 5 -
Growth of Bifidobacterium sp. isolates in the presence of unconjugated cholic acid (CA)
CHOLIC ACID (mM)
STRAIN : 0 1 3 5 35612 + + + + 35624 + + + + 35652 + + - - : 35658 + + - - 35687 + + - - . -, no growth; +, confluent growth
Example 4
Antimicrobial Activity
Bifidobacterium species exert inhibitory effects on other bacteria by excluding long term colonisation by invasive pathogens. Their antagonistic activity is due to the production of acetic and lactic acid though fermentation (Scardovi, V. (1986)
Bifidobacterium in Bergey's Manual of systemic bacteriology, Vol. 2. Eds. Sheath,
P.H., Main, N.S,, Sharpe, M. and Holdt, J.G., Williams and Wilkins Publishers,
Baltimore M.D., pl418). Very few reports exist on the production of antimicrobial compounds other than acids (Anand, S.K. et a/. Cult. Dairy Prods. 1985;J. 2, 21-23). Bacteriocins and other compounds may infiuence the survival of a bacterium in an ecological niche and allow them to effectively dominate fermenting ecosystems. Such a feature is a good trait for a probiotic strain.
‘
The inhibitory spectra of various bifidobacterial strains was determined by the method of Tagg er al. (Tagg. J.R. et al. Bacteriol. Rev. 1976; 40, 722-756). Cell free supernatant was assayed for inhibitory activity against a wide range of Gram positive and Gram negative micro-organisms. Overlays of each indicator were prepared on agar plates and allowed to dry. Spots (5ml) of cell free supernatant were placed on the seeded plates, allowed to dry and the plates were incubated overnight.
It was observed that the strains were inhibitory to a wide range of Staphylococcus,
Pseudomonas, Coliform and Bacillus sp. when testes on TPY medium. Zones of inhibition of up to 4.4 mm were recorded against Pseudomonas and
Staphylococcus and up to 7.0 mm surrounding Bacdius sp. as shown in Tables 6 and 7. However, when the deferred assays were performed on buffered TPY medium zones of inhibition were not observed against any indicator strain.
Therefore, inhibition appeared to be solely due to the presence of acid produced by the bifidobacteria.
- Table 6 :
Inhibition of Staphylococcus strains by Bifidobacterium sp. on unbuffered medium* - oO — [= — 5 € E
ES 3) & NF NN 0 wn © § § 3 SS 8 25k 8
EE mm 8 4 8&8 8 8 8 8 4
S. aureus MHS 1.5 2 15 35 15 1 2 2 1 25 15
S. aureus HC 1.5 15 2 25 2 15 25 2 15 15 2
S. aureus 771 1.5 3 15 3 2 2 25 2 3 2 35
S. aureus 949 2 35 25 2 3 35 3 25 35 35 25
S. aureus 1018 1 35 15 15 2 35 1 3 35 25 2
S. aureus 1502 1.5 35 1 2 25 25 15 3 4 25 15
S. aureus 1505 3 4 3 25 25 3 25 45 55 5 55
S. aureus 1511 1 35 2 15 2 25 3 35 4 25 3
S. aureus 1522 15 3 25 1 25 15 25 25 35 35 3
S. aureus 1499 15 35 15 1.5 2 2 3 2 35 35 15
S. aureus 1963 Z 53 2 25 35 35 35 35 25 3 25
S. aureus PRMM 1 35 1 15 1 35 2 2 3 2 25
S. albus 1 2 15 1 2 25 2 15 2 15 1
S. camosus 1 15 2 25 25 25 2 25 2 15 1 * values given are radii of inhibition zones in mm (distance from edge of producer colony to the edge of zone of inhibition) :
- Table 7
Inhibition of Pseudomonas and Bacillus strains by Bifidobacterium sp. on unbuffered medium* z
J
- = — on —
I~) I~ = ol <X ol ea] [To oa ~ $88 SF EEEEE fo] /m m \O on on on on py m PA -
P. fluorescens HC. 1025 15 1 15 2 3 2 15 2 Z5
P. fuorescens MHF 1.5 45 35 2 25 35 25 25 35 2 4
P. AuorescensDW 1.5 4 4 35 25 35 25 45 55 35 ©
B. cereus 3 3 5 3 4 4 35 35 6 45 535
B. subtilis 2 25 5 2 3 6 3 6 7 3 6
B. circulans 1 2 4 15 25 15 2 35 45 2 45
B thuringensis 25 35 = 3 33 45 4 53% 83 45 55 *, values given are radii of inhibition zones in mm (distance from edge of producer colony to the edge of zone of inhibition)
__WOou/42168 ~ _ ~. . _ FCT/IE00/00008 a
Murine Feeding trial to investigate the ability of Lactobacill livariu, . ivarius 118 a ifidobacteria longum infantis 35624 to alleviate the f Inflamm wel di D
A number of mouse models have recently been generated by either genetic or immunological means to study the mechanisms of IBD. One of these models involves the transfer of spleen or lymph node-derived CD4'T lymphocytes from normal mice into severe combined immunodeficient recipient mice (SCID). It has been demonstrated that mice who receive purified CD4*, CD45RB™* T cells develop a wasting disease characterised by chronic intestinal inflammation which is more severe in the colon. In this study a control group of SCID mice was
RB injected with CD4* CD45RB"® and the mice developed a progressive wasting disease including hunched over appearance, piloerection of the coat, diarrhoea, weight loss and macro and microscopic colon damage. A feeding trail was set up administering UCC 118 and strain 35624 (also referred to herein as UCC 35624) to determine if the symptoms of IBD could be modified in this model.
Bacterial strains
Lactobacillus salivarius subsp. Salivarius UCC 118 and Bifidobacterium longum infantis UCC 35624 were isolated from the ileal-caecal region of an adult human as described in Example 1. In this example, spontaneous rifampicin and streptomycin resistant derivatives of the strains were generated by plating cells, previously grown overnight and subsequently washed in quarter strength Ringer's ’ soluticn on MRS and TPY agar containing 50ug/ml rifampicin (Sigma) respectively and MRS containing 400pg/ml streptomycin (Sigma). Plates were incubated for 2 days at 37°C anaerobically. The resulting antibiotic resistant
- derivatives were determined to be otherwise phenotypically similar to the parent strain. This selectable trait enabled the strains to be readily enumerated following gut transit.
Animals and maintenance
Donor mice (C57BL/6 x BALB/c) F1 were purchased from Simosen
Laboratories (Gilroy, CA) and maintained at the University of California — Los
Angeles vivarium in ventilated cage racks (Thoren caging systems, Hazelton, PA) under specific pathogen free (SPF) conditions. CB-17 SCID mice were bred in ventilated cage racks originally obtained from the University of California — Los
Angeles SCID core facility. The mice were reduced flora (RF) mice rather than germ free and acting as the recipient mice (Aranda R. er al. J. of Immunol. 1997, 158(7), 3464-3473).
Eight week old, female CB-17 (SCID) mice were housed in pairs in filter top cages } in ventilated racks. The mice were divided into four groups Group A: consumed 10% skim milk, control; Group B: consumed Lactobacillus salivarius UCC 118,
Group C: consumed Lactobacillus salivarius UCC 118 and Bifidobacterium
Jongurn UCC 35624 9 (1:1 ratio); Group D: consumed Bifidobacterium longum
UCC 35624. UCC 118 and UCC 35624 which were grown overnight in MRS broth and MRS broth supplemented with 0.05% cysteine (Sigma) respectively, were washed in PBS, resuspended in skim milk (10% (v/v)) and administered in the otherwise sterile drinking water (PBS). The mice in each respective group received 2.55X10° cfu/ml of UCC 118 and 2.35x10° cfu/ml of UCC 35624 daily for the duration of the feeding period. Control mice received sterile milk diluted in sterile phosphate buffered saline (PBS) and were maintained under identical conditions as the test group.
3 Experimental design :
All CB-17 mice were administered their respective feed according to their grouping for 2 days prior to injection with the CD4* CD45RB" cells. The sorted h) donor lymphocytes (3-4 x 10°) were represented in 200ul of sterile PBS and injected i.p. into the recipient CB-17 SCID mice. All mice were weighed initially, then twice weekly thereafter. They were observed for clinical signs of illness: hunched over appearance, piloerection of the coat and diarrhoea.
Evaluation of the effects of the administered probiotics on the numbers of indigenous bacteria culturable from mouse faeces.
The influence exerted by the administered UCC 118 and UCC 35624 when either administered alone or in combination with each other, on the microflora of the
CB-17 SCID murine gut was investigated. Faecal samples were collected from each mouse weekly, weighed and resuspended in 10ml PBS. The samples were then serially diluted in PBS and either pour plated or spread plated in appropriate dilutions on appropriate media in duplicate. The following bacterial groups were enumerated: lactobacilli; bifidobacteria; enterococci; bacteroides and coliforms.
The selective media used were; de Mann Rogosa & Sharpe (MRS) agar; MRS agar supplemented with 0.2% lithium chloride (BDH), 0.3% sodium propionate (Fluke chemie), 0.5% cysteine hydrochloride (Sigma), and 5% sheep’s blood;
Slanetz and Bartley agar; Wilkins and Chalgren agar supplemented with anaerobic supplement SR 108 and 5% horse blood; and Violet Red Bile Agar. (All Oxoid unless otherwise stated). VRBA and Slanetz and Bartley plates were incubated aerobically for 24 and 45 h respectively. All other plates were incubated anaerobically for 48 h at 37°C.
- Enumeration of culturable indigenous flora from specific segments of the CB.17
SCID murine G.1.T.
After the feeding period all mice were sacrificed and dissected. Segments of the ileal-caecal region, small intestine, and the large intestine were removed. A peripheral lymph node (PLN), mesenteric lymph node (MLN) and a piece of the spleen were also taken. All tissues were weighed before being resuspended in 10 ml of PBS. Samples were then homogenised and serially diluted in PBS and either spread plated or pour plated in appropriate dilutions on appropriate media in duplicate. The bacterial groups were enumerated the same as those enumerated in the faecal analysis and samples were incubated as described previously.
Preparation of intraepithelial and lamiinapropria lymphocytes
The isolation of the mucosal lymphocytes was carried out according to the method of Aranda, R. era/ (1997) supra).
Flow cytometric analysis of lymphocyte populations,
The analysis was conducted as described by Aranda, R. eral ((1997) supra)
Preparation of tissue for histopathological analysis
Tissue samples were taken from the small intestine, large intestine, and ileal caecal region and fixed in 10% formalin. The procedure was as described in
Aranda, R. eral ((1997) supra).
It was observed from the experiment carried out that, consistent with previous results, the SCID mice reconstituted with CD4* CD45RB™* T lymphocytes and consuming skim milk alone (control) developed a progressive wasting disease,
_WOoo0/42168 EE ~PCT/IE00/00008 _ : identified by their significant weight loss. Disease became apparent at about 2 } and a half to three weeks and the sick mice characteristically manifested a hunched over appearance, piloerection of their coat, and loose stool. One of the mice in the control group (mouse 4) died after 25 days and mice 1, 2, 3 and 5 showed a —20%, 25%, 21% and -35% percentage weight change respectively as depicted in Figs. 3 and 4.
CB-17 SCID mice consuming UCC 118 alone gave a similar result as the controls with the characteristic weight loss. Mouse 3 died after 14 days, and mice 4, 5 and 6 showed a —15%, -25% and -28% percentage weight change respectively (data not shown). The mice consuming a combination of UCC 118 and UCC 35624 were found to have a marked improvement on the control mice. These mice did not lose as much weight as the control mice over the feeding period. Even after 35 days three of the mice in this group showed little percentage weight change. (Figs. 5 and 6). Two of the mice in this group showed a weight loss only after n about 30 days whereas control mice showed weight loss at 14 days (Figs. 3 and 4).
Mice consuming UCC 35624 alone appeared in good health and again weight loss when compared to the controls was considerably less (Figs. 7 and 8). It can be concluded therefore that consumption of UCC 35624 either alone or in combination with UCC 118 alleviates the symptoms of inflammatory bowel disease.
Table 8 is a summary of experimental data for the study on the treatment of
CD45RB colitis induced CB17 and SCID mice with a cocktail of UCC 118 and
UCC 35624.
It was found in the studies that the mice were successfully reconstituted with lymphocytes and lymphocytes having been derived from the donor model (data not shown).
. Table 8
Treatment of CD45RB colitis induced CB 17 SCID mice with a cocktail of
Lactobacillus salivarius UCC 118 and Bifidobacteria.
Organ Mouse 1 Mouse 2 Mouse 3 Mouse 4 | Mouse 5 Mouse 6
Untreated Untreated Cocktail Cocktail | Cocktail | Cocktail {RB hi cells | (RB hi cells Treated Treated Treated Treated + skimmed | + skimmed milk milk loss i Appearance | health
Appearance
Colon thickened slightly slight slightly slight
Appearance thickened thickened | proximal | thickened proximal ! thickening | thickening l' No. STEL 100,000 200,000 0 0 ! 512,000 © 28,000 : 384,000 96,000 104,000
No. LLPL 256,000 160,000
No. MLN 0 N/A | 81,500 N/A 28.800 N/A
No.PLN 0 192,000 0 120,000 64,000 0
Spleen # 960,000 512,000 640,000 640,000 512,000 6,400,000 65,280 :
No. LLPL 67,200 161,280 115200 108.000 | 184.320 | 108.300
No.MLN | 0 [| N/A | 13000 N/A 64,000 N/A
No.PLN | 0 | 126,720 0 87,600 54,400 0
I Spleen | 518400 | 102,400 | 211200 307,200 | 230,400 | 4,480,000 !
UCC 118 bacterial counts (per biopsy) post mortem st To T° oo "FT 120 [ 0 [0 | 0
Li 0 11,600
Caecum 0 0 >30,000 | >30,000 >30,000 | >30,000
Spleen | 0 [0 oo [ 130 [0 | 0
Colon Pathological Scoring _A@©3) [oT we Tie [20 To [0 - _ B@2 | 15 [wo [we | Fo] cE) [2s Tw [20 [o-oo] bed [ - 20 1 30 © 30 [ 0- | - _E@3» [| - wo | ie a0 7-0-0]
Remarks [ ~~ [~~ ~~ 7] : (TomlScore | — - | 80 | 70 | we [-[ - |]
A: Degree of inflammatory infiltrate; B: Mucin depletion; C: Epithelia hyperplasia; ID: No. of TEL in the crypts; E: No. of inflammatory foci per high power fields
. Ce WO0042168 eee ___PCT/IE00/00008 NB : Example 7 :
Overnight washed cultures of Bifidobacteria were incubated with human peripheral blood mononuclear cells (PBMCs) from both healthy volunteers (n=9) and patients suffering from inflammatory bowel disease (n=>5). Production of the proinflammatory cytokine tumour necrosis factor o (TNFa) was measured by
ELISA in seventy two hour culture supernatants. Co-incubation of
Bifidobacterium Jongum infantis with human PBMCs did not result in the stimulation of TNFa production (Figure 9). Thus, exposure of the systemic immune system to this bacterium does induce an inflammatory response.
In order to assess the immune perception of Bifidobacterium longum infantis at mucosal surfaces, co-culturing of epithelial cells and PBMCs was performed in . transwell chambers. Briefly, an epithelial cell monolayer was grown in the upper chamber and PBMCs were incubated in the lower compartment. These were
Lo seperated from each other by a porous membrane which allowed the passage of soluble mediators between the two compartments but did not allow cell-cell contact. Using this model, the production of TNFa and Interleukin-8 (IL-8) was measured in the presence and absence of Bifidobacterium longum infantis in the
PBMC compartment. Co-culture of epithelial cells, PBMCs and Bifidobacterium longum infantis resulted in significant suppression of TNFa and IL-8 production (Figure 10). Thus, a tri-cellular network involving epithelial cells, PBMCs and
Bifidobacterium longum infantis results in suppression of proinflammatory cytokine production.
- Example 8
In vivo anti-inflammatory activity of Bifidobacterium longum infantis
Bifidobacterium longum infantis (1x10° cells per day) was consumed by 18 healthy humans in a fermented milk (yoghurt) product for three weeks. Serum was collected for cytokine analysis pre and post consumption of this probiotic strain. Faecal samples were obtained for microbiological analysis.
Considerable modification of peripheral blood cytokine levels were observed in this feeding study. Serum soluble Interleukin-6 receptor (sIL-6R, p=0.007),
Interferon-y (IFNy, p=0.041) and IL-8 (p=0.004) levels were significantly reduced following consumption of this probiotic strain (Figure 11). No alteration in serum
TNFa and Interleukin-1 receptor antagonist (IL-1RA) levels were observed (Figure 12). Bifidobacterium Jongum infantis was detected at approximately 1x10° colony forming units per gram of faecal matter over the course of this feeding study.
Targeted in vitro selection criteria reflecting the complex interactions of the GI . environment allow for the identification of probiotic strains capable of functioning effectively when reintroduced inte that environment. Using the selection criteria outlined above, the probiotic bacteria Bifidobacterium longum infantis has demonstrable immunomodulating properties in vitro. Following consumption by
SCID mice and human volunteers, significant modification of systemic immune parameters was noted. Thus, the use of Bifidobacterium longum infantis as a biotherapeutic agent in the treatment of immune mediated diseases is warranted.
. bo :
Example 9 -
Measurement of TNFa _in Bifidobacterium longum infantis UCC 35624 cell free supernatant
Overnight cultures of Bifidobacterium longum infantis were centrifuged and the cell-free culture supernatant was examined for the presence of cytokine inhibitors.
Cell free supernatants were incubated with human TNFa for 20 minutes at 37°C.
TNFa. levels were quantified thereafter by ELISA. Following exposure to the
Bifidobacteria supernatant, TNFa levels were significantly reduced (Figure 13).
Thus, Bifidobacterium longum infantis UCC35624 secretes a factor that antagonises TNFa activity. Production of this factor by Bifidobacterium longum infantis at the surface of the gastrointestinal tract, 7n vivo, would significantly restrict the host inflammatory response.
This indicates that the antagonism of TNFa also occurs at a molecular level due to a soluble factor released by UCC 35624
Inflammation
Inflammation is the term used to describe the local accumulation of fluid, plasma proteins and white blood cells at a site that has sustained physical damage, infection or where there is an ongoing immune response. Control of the inflammatory response is exerted on a number of levels (for review see Henderson
B., and Wilson M, 1098 In “Bacteria-Cytokine interactions in health and disease,
Portland Press, 79-130). The controlling factors include cytokines, hormones (e.g. hydrocortisone), prostaglandins, reactive intermediates and leukotrienes.
Cytokines are low molecular weight biologically active proteins that are involved in the generation and control of immunological and inflammatory responses, while also regulating development, tissue repair and haematopoiesis. They provide a means of communication between leukocytes themselves and also with other cell types. Most cytokines are pleiotrophic and express multiple biologically
- overlapping activities. Cytokine cascades and networks control the inflammatory response rather than the action of a particular cytokine on a particular cell type (Arai KI, et al, Annu Rev Biochem 1990;59:783-836). Waning of the inflammatory response results in lower concentrations of the appropriate activating signals and other inflammatory mediators leading to the cessation of the inflammatory response. TNFa is a pivotal proinflammatory cytokine as it initiaies a cascade of cytokines and biological effects resulting in the inflammatory state. Therefore, agents which inhibit TNFa are currently being used for the treatment of inflammatory diseases, e.g. infliximab.
Pro-inflammatory cytokines are thought to play a major role in the pathogenesis of many inflammatory diseases, including inflammatory bowel disease (IBD).
Current therapies for treating IBD are aimed at reducing the levels of these pro- inflammatory cytokines, including IL-8 and TNFa. It has been suggested that such therapies may also play a significant role in the treatment of systemic inflammatory diseases such as rheumatoid arthritis. Humans fed with yoghurt containing Bifidobacterium longum infantis UCC35624 have shown marked decreases in their systemic levels of IL-8. This strain may therefore have potential application in the treatment of a range of flammatory diseases, particularly if used in combination with current anti-inflammatory therapies, such as non-steroid anti-inflammatory drugs (NSAIDs) or Infliximab.
Diarrhoeal Disease.
The barrier function of the intestinal epithelium can be diminished during nervous (acetylcholine) and immune (histamine) mediated secretion. Certain bacterial toxins may also induce Ca2+ and PKC dependent secretion and thereby can disturb the epithelial barrier (Ganguly NK and Kaur T. Indian J Med Res 1996,104:28-37, Groot JA. Vet Q 1998;20(53):45-9). Several studies have examined the prevention and treatment of diarrhoea using probiotic bacteria.
Prospective studies have demonstrated the efficacy of lactic acid bacteria administration for both prophylactic and therapeutic use against diarrhoea in pre-
- mature infants, new borns, children (Isolauri E, et al, Dig Dis Sci 1994 CT
Dec;39(12):2595-600) and in the treatment of antibiotic related diarrhoea (Siitonen S, et al, Ann Med 1990 Feb;22(1):57-9) and traveller's diarrhoea (Oksanen PJ, et al., Ann Med 1990 Feb;22(1):53-6).
We have examined consumption of Bifidobacterium longum infantis UCC 35624 by SCID mice. It was found that inflammatory activity was significantly attenuated and mice consuming Bifidobacterium longum infantis UCC 35624 retained solid stools while control mice suffered from diarrhoea. Figs. 14 and 15 illustrate the lower intestine of treated and untreated SCID mice. The lower intestine shown includes the caecum 2, intestine 3 and anus 5. In Fig. 14 the mice were treated with Bifidobacterium longum infantis UCC 35624 and it is apparent that solid stools 4 have been retained in the intestine. In comparison Fig. 15 shows the untreated mouse intestine 3, characteristically inflamed. No water absorption has occurred so that no solid stools are retained resulting in diarrhoea.
The anti-diarrhoeal effect observed may be related to the anti-inflammatory activity, possibly mediated via CAMP modulation. Cyclic AMP-dependent Cl- secretion is the major secretory pathway in the human intestine (Brzuszczak IM, et al., J. Gastroenterol. Hepatol. 1996;11(9):804-10). It can be inferred that the anti-diarrhoeal effect of Bifidobacterium longum infantis UCC 35624 is not restricted just to diarrhoea resulting from gastrointestinal inflammation, but can be applied to the general treatment of diarrhoeal disease.
Autoimmune Disease
The immune system has a large repertoire of specificities expressed by B and T cells. Some of these specificities will be directed to self-components. Self- recognition is normally controlled by clonal deletion and inactivation of self- i reactive lymphocytes. However, there is a constant background of autoimmunity with antibodies to many proteins being found in serum. A breakdown in the self- nonself recognition system results in autoimmunity. When autoimmune disease
- does occur, the resulting immune response damages the tissue bearing the offending antigen. Immune complex deposition, type II hypersensitivity and cell- mediated reactions are the most important mechanisms by which immunopathological damage occurs. Examples of autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, insulin dependent diabetes mellitus, myasthenia gravis and pernicious anaemia.
Bifidobacterium longum infantis and Lactobacillus salivarius subsp. salivarius are immunomodulatory bacteria. Thus, consumption either as single components or in combination of these bacteria by patients suffering from autoimmune disease may restrict organ damage and help restore normal body homeostasis.
Inflammation and Cancer
The production of multifunctional cytokines across a wide spectrum of tumour types suggests that significant inflammatory responses are ongoing in patients with cancer. It is currently unclear what protective effect this response has against the growth and development of tumour cells in vivo. However, these inflammatory responses could adversely affect the tumour bearing host. Complex cytokine interactions are involved in the regulation of cytokine production and cell proliferation within tumour and normal tssues McGee DW, et al., Immunclogy 1995 Sep;86(1):6-11, Wu S, et al., Gynecol Oncol 1994 Apr;53(1):59-63). It has long been recognised that weight loss (cachexia) 1s the single most common cause of death in patients with cancer (Inagaki J, et al., Cancer 1974 Feb;33(2):568-73) and initial malnutrition indicates a poor prognosis (Van Eys J. Nutr Rev 1982
Dec;40(12):353-9). For a tumour to grow and spread it must induce the formation of new blood vessels and degrade the extracellular matrix. The inflammatory response may have significant roles to play in the above mechanisms, thus contributing to the decline of the host and progression of the tumour. Due to the anti-inflammatory nature of these bacterial strains, they may reduce the rate of malignant cell transformation. Furthermore, intestinal bacteria can produce, from dietary compounds, substances with genotoxic, carcinogenic and tumour- promotng activity and gut bacteria can activate pro-carcinogens to DNA reactive
: ...Wooo/42168 ~~ _ PCI/IE00/00008 : agents (Rowland LR. (1995). Toxicology of the colon: role of the intestinal } microflora. In: Gibson G.R. (ed). Human colonic bacteria: role in nutrition, physiology and pathology, pp 155-174. Boca Raton CRC Press). In general, species of Bifidobacteria and Lactobacillus have low activities of xenobiotic metabolising enzymes compared to other populations within the gut such as bacteroides, eubacteria and clostridia (Saito Y., et al., Microb. Ecol. Health Dis., 1992;5, 105-110). Therefore, increasing the number of lactic acid bacteria in the gut could beneficially modify the levels of these enzymes.
Prebiotics
The introduction of probiotic organisms is accomplished by the ingestion of the microorganism in a suitable carrier. It would be advantageous to provide a medium that would promote the growth of these probiotic strains in the large bowel. The addition of one or more oligosaccharides, polysaccharides, or other
Bn prebiotics enhances the growth of lactic acid bacteria in the gastrointestinal tract : (Gibson, GR. Br. J. Nutr. 1998;80 (4):S209-12). Prebiotics refers to any non- viable food component that is specifically fermented in the colon by indigenous bacteria thought to be of positive value, e.g. bifidobacteria, lactobacilli. Types of prebiotics may include those which contain fructose, xylose, soya, galactose, glucose and mannose. The combined administration of a probiotic strain with one or more prebiotic compounds may enhance the growth of the administered probiotic in vivo resulting in a more pronounced health benefit, and is termed synbiotic.
Other active ingredients
It will be appreciated that the Bifidobacterium may be administered prophylactically or as a method of treatment either on its own or with other probiotic and/or prebiotic materials as described above. In addition, the bacteria may be used as part of a prophylactic or treatment regime using other active materials such as those used for treating inflammation or other disorders,
- especially those of the gastrointestinal tract. Such combinations may be administered in a single formulation or as separate formulations administered at the same or different times and using the same or different routes of administration.
The invention is not limited to the embodiments hereinbefore described which may be vaned in detail,
Claims (50)
1. A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract which is significantly immunomodulatory following oral consumption in humans.
2. A strain of Bifidobacterium as claimed in claim 1 which effects changes in an immunological marker when introduced into a system comprising cells which interact with the immune system and cells of the immune system.
3. A strain of Bifidobacterium as claimed in claim 2 wherein the cells which interact with the immune system are epithelial cells.
4, A strain of Bifidobacterium as claimed in claim 2 or 3 wherein the immunological marker is a cytokine.
5. A strain of Bifidobacterium as claimed in claim 4 wherein the cytokine is TNFa.
6. A strain of Bifidobacterium as claimed in any of claims 2 to 5 wherein the cells which interact with the immune system and the immune system cells are of matched origin.
7. A strain of Bifidobacterium as claimed in any of claims 2 to 6 wherein the cells which interact with the immune system are of gastrointestinal, respiratory or genitourinary origin.
8. A strain of Bifidobacterium as claimed in any of claims 2 to 6 wherein the - cells of the immune system are of gastrointestinal, respiratory or : genitourinary origin.
- 9. A strain of Bifidobacterium longum infantis isolated from resected and washed human gastrointestinal tract which is significantly immunomodulatory following oral consumption in humans.
10. A strain of Bifidobacterium as claimed in any of claims 1 to 9 which has significant anti-inflammatory effect following oral consumption in humans.
11. A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract which is capable of combating the effects of inflammatory bowel disease, said capability being maintained in the presence of physiological concentrations of human bile and human gastric juice.
12. A strain of Bifidobacterium longum mfantis according to claim 11, wherein the capability of combating the effects of inflammatory bowel disease is measured by measuring a reversal of a wasting disease induced in severe combined immunodeficient recipient mice (SCID) which have been administered purified CD4*, CD45RB¥#" T cells.
13. A strain of Bifidobacterium as claimed in any preceding claim, which has inhibitory activity against a broad range of Gram positive and Gram negative bacteria.
14. A strain of Bifidobacterium as claimed in preceding claim, wherein the strain exhibits a broad-spectrum of activity against bacteria including Staphylococcus, Pseudomonas, Coliform and Bacillus species.
15. A strain of Bifidobacterium longum infantis UCC35624 or mutant or variant thereof.
16. A strain of Bifidobacterium longum infantis UCC35624 as claimed in N claim 15 wherein the mutant is a genetically modified mutant.
17. A strain of Bifidobacterium longum infantis UCC35624 as claimed in claim 15 wherein the variant is a naturally occurring variant of Bifidobacterium longum mfantis UCC35624.
18. A strain of Bifidobacterium as claimed in any of claims 1 to 17 in the form of viable cells.
19. A strain of Bifidobacterium as claimed in any of claims 1 to 17 in the form of non-viable cells.
20. An antimicrobial agent obtained from a strain of Bifidobacterium as claimed in any of claims 1 to 19 which is antagonistic to the growth of a other organisms.
21. A formulation which comprises a strain of Bifidobacterium as claimed in any of claims 1 to 19.
22. A formulation as claimed in claim 21, which comprises two or more strains of Bifidobacterium.
23. A formulation as claimed in claim 21 or 22, which includes another probiotic material.
24. A formulation as claimed in any of claims 21 to 23, which includes a prebiotic material.
25. A formulation as claimed in any of claims 21 to 24, which includes a strain of Lactobacillus salivarius.
- 26. A formulation as claimed in claim 25 wherein the strain of Lactobacilius salivarius is in the form of viable cells.
27. A formulation as claimed in claim 25 wherein the strain of Lactobacillus salivarius is in the form of non-viable cells.
28. A formulation as claimed in any of claims 25 to 27, wherein the Lactobacillus salivarius is isolated from resected and washed human gastrointestinal tract, the Lactobacillus salivarius being significantly immunomodulatory following oral consumption in humans.
29. A formulation as claimed in any of claims 25 to 28, wherein the strain of Lactobacillus salivarius 1s isolated from resected and washed human gastrointestinal tract which inhibits a broad range of Gram positive and Gram negative micro-organisms.
30. A formulation as claimed in any of claims 25 toc 29 wherein the strain of Lactobacillus salivarius secretes a product having antimicrobial activity nto a cell — free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E, the inhibitory properties of said strain and its secretory products being maintained in the presence of physiological concentration of human bile and human gastric juice.
31. A formulation as claimed in any of claims 25 to 30, wherein the strain of Lactobacillus salivarius is Lactobacillus salivarius strain UCC 118 or a mutant or variant thereof.
32. A strain of Lactobacillus salivarius strain UCC 118 as claimed in claim 31 wherein the mutant is a genetically modified mutant.
: 33. A strain Lactobacillus salivarius strain UCC 118 as claimed in claim 31 - wherein the variant is a naturally occurring variant of Lactobacillus salivarius.
34. A formulation as claimed in any of claims 21 to 33 which includes an ingestable carrier.
35. A formulation as claimed in claim 34 wherein the ingestable carrier is a pharmaceutically acceptable carrier such as a capsule, tablet or powder.
36. A formulation as claimed in claim 35 wherein the ingestable carrier is a food product such as acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings or beverages.
37. A formulation as claimed in any of claims 21 to 36 which further oo comprises a protein and/or peptide, in particular proteins and/or peptides that are rich in glutamine/glutamate, a lipid, a carbohydrate, a vitamin, mineral and/or trace element.
38. A formulation as claimed in claims 21 to 37 wherein the Bifidobacterium is present at more than 10° cfu per gram of delivery system.
39. A formulation as claimed in claims 21 to 38 which includes an adjuvant.
40. A formulation as claimed in claims 21 to 39 which includes a bacterial component.
41. A formulation as claimed in claims 21 to 40 which includes a drug entity.
42. A formulation as claimed in claims 21 to 41 which includes a biological compound.
43. A formulation as claimed in claims 21 to 42 for oral immunisation
44. A strain of Bifidobacterium as claimed in any of claims 1 to 19 or a formulation as claimed in any of claims 21 to 43 for use in foodstuffs.
45. A strain of Bifidobactersum as claimed in any of claims 1 to 19 or a formulation as claimed in any of claims 21 to 43 for use as a medicament.
46. A strain of Bifidobacterium as claimed in any of claims 1 to 19 or a formulation as claimed in any of claims 21 to 43 for use in the prophylaxis and/or treatment of undesirable inflammatory activity.
47. A strain of Bifidobacteriurz as claimed in any of claims 1 toc 19 or a formulation as claimed in any of claims 21 to 43 for use in the prophylaxis and/or treatment of undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohns disease or ulcerative colitis, irritable bowel syndrome; pouchitis; or post infection colitis.
48. A strain of Bifidobacterium as claimed in any of claims 1 to 19 or a formulation as claimed in any of claims 21 to 43 for use in the prophylaxis and/or treatment of gastrointestinal cancer(s).
49. A strain of Bifidobacterium as claimed in any of claims 1 to 19 or a formulation as claimed in any of claims 21 to 43 for use in the prophylaxis and/or treatment of systemic disease such as rheumatoid arthritis.
50. A strain of Bifidobacterium as claimed in any of claims 1 to 19 or a formulation as claimed in any of claims 21 to 43 for use in the prophylaxis and/or treatment of autoimmune disorders due to undesirable inflammatory activity.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE990033A IE990033A1 (en) | 1999-01-15 | 1999-01-15 | Bifidobacterium longum infantis in the treatment of inflammatory bowel disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200105617B true ZA200105617B (en) | 2002-10-22 |
Family
ID=27620462
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200105616A ZA200105616B (en) | 1999-01-15 | 2001-07-09 | Use of lactobacillus salivarius. |
ZA200105617A ZA200105617B (en) | 1999-01-15 | 2001-07-09 | Bifidobacterium in the treatment of inflammatory disease. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200105616A ZA200105616B (en) | 1999-01-15 | 2001-07-09 | Use of lactobacillus salivarius. |
Country Status (2)
Country | Link |
---|---|
IE (1) | IE990033A1 (en) |
ZA (2) | ZA200105616B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003243545A1 (en) * | 2002-06-14 | 2003-12-31 | Amylin Pharmaceuticals, Inc. | Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof |
ITMI20120471A1 (en) * | 2012-03-26 | 2013-09-27 | Giovanni Mogna | COMPOSITION BASED ON BACTERIA BIFID BACTERIUM LONGUM STRIPS ABLE TO HELP THE EXTENSION OF LIFE |
EP4032536A1 (en) * | 2021-01-26 | 2022-07-27 | Probisearch, S.L.U. | Probiotic composition for infants and its uses |
-
1999
- 1999-01-15 IE IE990033A patent/IE990033A1/en unknown
-
2001
- 2001-07-09 ZA ZA200105616A patent/ZA200105616B/en unknown
- 2001-07-09 ZA ZA200105617A patent/ZA200105617B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200105616B (en) | 2002-02-25 |
IE990033A1 (en) | 2000-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1141235B1 (en) | (bifidobacterium) in the treatment of inflammatory disease | |
EP1409645B1 (en) | Probiotic lactobacillus salivarius strains | |
US20030092163A1 (en) | Probiotic bifidobacterium strains | |
AU2002329007A1 (en) | "Probiotic Lactobacillus salivarius strains" | |
ZA200105617B (en) | Bifidobacterium in the treatment of inflammatory disease. | |
IE20000034A1 (en) | Bifidobacterium in the treatment of Inflammatory Disease | |
ZA200400555B (en) | Probiotic bifidobacterium strains. | |
IE20020626A1 (en) | Probiotic Bifidobacterium strains |